These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1081 related articles for article (PubMed ID: 28552047)
1. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial. Okines AF Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047 [TBL] [Abstract][Full Text] [Related]
2. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681 [TBL] [Abstract][Full Text] [Related]
3. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696 [TBL] [Abstract][Full Text] [Related]
4. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717 [TBL] [Abstract][Full Text] [Related]
5. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). de Haas SL; Slamon DJ; Martin M; Press MF; Lewis GD; Lambertini C; Prat A; Lopez-Valverde V; Boulet T; Hurvitz SA Breast Cancer Res; 2023 Jan; 25(1):2. PubMed ID: 36631725 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Therapy for HER2-positive Breast Cancer. Wuerstlein R; Harbeck N Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890 [TBL] [Abstract][Full Text] [Related]
8. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092 [TBL] [Abstract][Full Text] [Related]
9. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Krop I; Winer EP Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Hurvitz SA; Martin M; Jung KH; Huang CS; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Fasching PA; Afenjar K; Spera G; Lopez-Valverde V; Song C; Trask P; Boulet T; Sparano JA; Symmans WF; Thompson AM; Slamon D J Clin Oncol; 2019 Sep; 37(25):2206-2216. PubMed ID: 31157583 [TBL] [Abstract][Full Text] [Related]
13. A systematic review of dual targeting in HER2-positive breast cancer. Kümler I; Tuxen MK; Nielsen DL Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156 [TBL] [Abstract][Full Text] [Related]
14. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Barginear MF; John V; Budman DR Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784 [TBL] [Abstract][Full Text] [Related]
16. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L; Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691 [TBL] [Abstract][Full Text] [Related]
17. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States. Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705 [TBL] [Abstract][Full Text] [Related]
18. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864 [TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Takano T; Masuda N; Ito M; Inoue K; Tanabe Y; Kawaguchi K; Yasojima H; Bando H; Nakamura R; Yamanaka T; Ishida K; Aruga T; Yanagita Y; Tokunaga E; Aogi K; Ohno S; Kasai H; Kataoka TR; Morita S; Toi M Breast Cancer Res Treat; 2024 Aug; 207(1):33-48. PubMed ID: 38767786 [TBL] [Abstract][Full Text] [Related]
20. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]